Modes of action of Leishmanicidal antimicrobial peptides

Future Microbiology

Volumn 7, Issue 9, 2012, Pages 1047-1059

  Marr, Alexandra K ^a,b   McGwire, Bradford S ^c   McMaster, W Robert ^a,b  

^a VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

antimicrobial peptide; apoptosis; immunomodulation; Leishmaniasis; membrane disruption

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; BOMBININ; BOMBININ H2; BOMBININ H4; BOVINE MYELOID ANTIMICROBIAL PEPTIDE; CATHELICIDIN; CECROPIN A; HISTATIN; HISTATIN 5; INDOLICIDIN; MAGAININ 1; MAGAININ 2; MAGAININ DERIVATIVE; MEGLUMINE ANTIMONATE; MELITTIN; MILTEFOSINE; PENTAMIDINE; POLYPEPTIDE ANTIBIOTIC AGENT; STIBOGLUCONATE SODIUM; TEMPORIN 1SA; TEMPORIN A; TEMPORIN B; TEMPORIN DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DEATH; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; LEISHMANIASIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTIPROTOZOAL AGENTS; APOPTOSIS; CELL MEMBRANE; HUMANS; IMMUNOMODULATION; LEISHMANIA; LEISHMANIASIS;

EID: 84866123666     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.85     Document Type: Review

References (110)

1. Zilberstein D. Physiological and biochemical aspects of Leishmania development. In: LEISHMANIA After the Genome. Myler PJ, Fasel N (Eds). Caister Academic Press, Norfolk, UK (2008).
2. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res. 123(3), 345-352 (2006).
3. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: A randomized dose-finding study. Trans. R. Soc. Trop. Med. Hyg. 90(3), 319-322 (1996).
4. Zijlstra EE, Siddig Ali M, El-Hassan AM et al. The treatment of kala-azar in the Sudan with sodium stibogluconate: A randomized trial of three dosage regimens. Trans. R. Soc. Trop. Med. Hyg. 87(3), 307-309 (1993).
5. Ameen M. Cutaneous and mucocutaneous leishmaniasis: Emerging therapies and progress in disease management. Expert Opin. Pharmacother. 11(4), 557-569 (2010).
6. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (viannia) infection. J. Infect. Dis. 193(10), 1375-1383 (2006).
7. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19(1), 111-126 (2006).
8. Bhattacharya SK, Sur D, Karbwang J. Childhood visceral leishmaniasis. Indian J. Med. Res. 123(3), 353-356 (2006).
9. Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin. Investig. Drugs 14(11), 1337-1346 (2005).
10. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther. Clin. Risk Manag. 3(5), 733-740 (2007).
11. Dorlo TP, Van Thiel PP, Huitema AD et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob. Agents Chemother. 52(8), 2855-2860 (2008).
12. Sundar S, Rai M, Chakravarty J et al. New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis. 47(8), 1000-1006 (2008).
13. Guffanti M, Gaiera G, Bossolasco S et al. Post-kala-azar dermal leishmaniasis in an HIV-1-infected woman: Recovery after amphotericin B following failure of oral miltefosine. Am. J. Trop. Med. Hyg. 79(5), 715-718 (2008).
14. Neal RA, Allen S, Mccoy N, Olliaro P, Croft SL. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35(5), 577-584 (1995).
15. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356(25), 2571-2581 (2007).
16. Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 88(6), 700-703 (1994).
17. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 88(6), 695-698 (1994).
18. El-On J, Sulitzeanu A, Schnur LF. Leishmania major: Resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment. Ann. Trop. Med. Parasitol. 85(3), 323-328 (1991).
19. Wasan KM, Wasan EK, Gershkovich P et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J. Infect. Dis. 200(3), 357-360 (2009).
20. Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: Dose and response. J. Glob. Infect. Dis. 2(2), 159-166 (2010).
21. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42(2), 352-357 (1998).
22. Purkait B, Kumar A, Nandi N et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 56(2), 1031-1041 (2012).
23. Hancock RE. Cationic peptides: Effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1(3), 156-164 (2001).
24. Sitaram N, Nagaraj R: HOST-defense antimicrobial peptides: Importance of structure for activity. Curr. Pharm. Des. 8(9), 727-742 (2002).
25. Rivas L, Luque-Ortega JR, Andreu D. Amphibian antimicrobial peptides and Protozoa: Lessons from parasites. Biochim. Biophys. Acta 1788(8), 1570-1581 (2009).
26. Kulkarni MM, McMaster WR, Kamysz W, McGwire BS. Antimicrobial peptide-induced apoptotic death of leishmania results from calcium-de pend ent, caspase-independent mitochondrial toxicity. J. Biol. Chem. 284(23), 15496-15504 (2009).
27. Lynn MA, Kindrachuk J, Marr AK et al. Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: Role of leishmanolysin in parasite survival. PLoS Negl. Trop. Dis. 5(5), e1141 (2011).
28. Kulkarni MM, Barbi J, McMaster WR, Gallo RL, Satoskar AR, McGwire BS. Mammalian antimicrobial peptide influences control of cutaneous Leishmania infection. Cell Microbiol. 13(6), 913-923 (2011).
29. Cobb SL, Denny PW. Antimicrobial peptides for leishmaniasis. Curr. Opin. Investig. Drugs 11(8), 868-875 (2010).
30. Yeung AT, Gellatly SL, Hancock RE. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol. Life Sci. 68(13), 2161-2176 (2011).
31. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24(12), 1551-1557 (2006).
32. Levine DP. Clinical experience with daptomycin: Bacteraemia and endocarditis. J. Antimicrob. Chemother. 62(Suppl. 3), iii35-iii39 (2008).
33. Schilling A, Neuner E, Rehm SJ. Vancomycin: A 50-something-year-old antibiotic we still don't understand. Cleve. Clin. J. Med. 78(7), 465-471 (2011).
34. Nation RL, Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin. Respir. Crit. Care Med. 28(6), 604-614 (2007).
35. McGwire BS, Kulkarni MM. Interactions of antimicrobial peptides with Leishmania and trypanosomes and their functional role in host parasitism. Exp. Parasitol. 126(3), 397-405 (2010).
36. Mor A. Multifunctional host defense peptides: Antiparasitic activities. FEBS J. 276(22), 6474-6482 (2009).
37. Simmaco M, Kreil G, Barra D. Bombinins, antimicrobial peptides from Bombina species. Biochim. Biophys. Acta 1788(8), 1551-1555 (2009).
38. McGwire BS, Olson CL, Tack BF, Engman DM. Killing of African trypanosomes by antimicrobial peptides. J. Infect. Dis. 188(1), 146-152 (2003).
39. Alberola J, Rodriguez A, Francino O, Roura X, Rivas L, Andreu D. Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis. Antimicrob. Agents Chemother. 48(2), 641-643 (2004).
40. Zhang K, Beverley SM. Phospholipid and sphingolipid metabolism in Leishmania. Mol. Biochem. Parasitol. 170(2), 55-64 (2010).
41. Salay LC, Nobre TM, Colhone MC et al. Dermaseptin 01 as antimicrobial peptide with rich biotechnological potential: Study of peptide interaction with membranes containing Leishmania amazonensis lipid-rich extract and membrane models. J. Pept. Sci. 17(10), 700-707 (2011).
42. Routier FH, Higson AP, Ivanova IA et al. Characterization of the elongating alpha-d-mannosyl phosphate transferase from three species of Leishmania using synthetic acceptor substrate analogues. Biochemistry 39(27), 8017-8025 (2000).
43. Wassef MK, Fioretti TB, Dwyer DM. Lipid analyses of isolated surface membranes of Leishmania donovani promastigotes. Lipids 20(2), 108-115 (1985).
44. Paila YD, Saha B, Chattopadhyay A. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. Biochem. Biophys. Res. Commun. 399(3), 429-433 (2010).
45. Ramos H, Valdivieso E, Gamargo M, Dagger F, Cohen BE. Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J. Membr. Biol. 152(1), 65-75 (1996).
46. Joshi PB, Kelly BL, Kamhawi S, Sacks DL, McMaster WR. Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol. Biochem. Parasitol. 120(1), 33-40 (2002).
47. Kulkarni MM, McMaster WR, Kamysz E, Kamysz W, Engman DM, McGwire BS. The major surface-metalloprotease of the parasitic protozoan, Leishmania, protects against antimicrobial peptide-induced apoptotic killing. Mol. Microbiol. 62(5), 1484-1497 (2006).
48. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55(1), 27-55 (2003).
49. Huang HW. Molecular mechanism of antimicrobial peptides: The origin of cooperativity. Biochim. Biophys. Acta 1758(9), 1292-1302 (2006).
50. Mangoni ML. Temporins, anti-infective peptides with expanding properties. Cell. Mol. Life Sci. 63(9), 1060-1069 (2006).
51. Chadbourne FL, Raleigh C, Ali HZ, Denny PW, Cobb SL. Studies on the antileishmanial properties of the antimicrobial peptides temporin A, B and 1Sa. J. Pept. Sci. 17(11), 751-755 (2011).
52. Mangoni ML, Saugar JM, Dellisanti M, Barra D, Simmaco M, Rivas L. Temporins, small antimicrobial peptides with leishmanicidal activity. J. Biol. Chem. 280(2), 984-990 (2005).
53. Abbassi F, Oury B, Blasco T et al. Isolation, characterization and molecular cloning of new temporins from the skin of the North African ranid Pelophylax saharica. Peptides 29(9), 1526-1533 (2008).
54. Wade D, Silberring J, Soliymani R et al. Antibacterial activities of temporin A analogs. FEBS Lett. 479(1-2), 6-9 (2000).
55. Wade D, Flock JI, Edlund C et al. Antibiotic properties of novel synthetic temporin A analogs and a cecropin A-temporin A hybrid peptide. Protein Pept. Lett. 9(6), 533-543 (2002).
56. Saviello MR, Malfi S, Campiglia P et al. New insight into the mechanism of action of the temporin antimicrobial peptides. Biochemistry 49(7), 1477-1485 (2010).
57. Zhao H, Rinaldi AC, Di Giulio A, Simmaco M, Kinnunen PK. Interactions of the antimicrobial peptides temporins with model biomembranes. Comparison of temporins B and L. Biochemistry 41(13), 4425-4436 (2002).
58. Rinaldi AC, Di Giulio A, Liberi M et al. Effects of temporins on molecular dynamics and membrane permeabilization in lipid vesicles. J. Pept. Res. 58(3), 213-220 (2001).
59. Zhao H, Kinnunen PK. Binding of the antimicrobial peptide temporin L to liposomes assessed by Trp fluorescence. J. Biol. Chem. 277(28), 25170-25177 (2002).
60. Mangoni ML, Maisetta G, Di Luca M et al. Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrug-resistant nosocomial bacterial strains. Antimicrob. Agents Chemother. 52(1), 85-91 (2008).
61. Krishnakumari V, Nagaraj R. Antimicrobial and hemolytic activities of crabrolin, a 13-residue peptide from the venom of the European hornet, Vespa crabro, and its analogs. J. Pept. Res. 50(2), 88-93 (1997).
62. Argiolas A, Pisano JJ. Isolation and characterization of two new peptides, mastoparan C and crabrolin, from the venom of the European hornet, Vespa crabro. J. Biol. Chem. 259(16), 10106-10111 (1984).
63. Jilek A, Mollay C, Tippelt C et al. Biosynthesis of a d-amino acid in peptide linkage by an enzyme from frog skin secretions. Proc. Natl Acad. Sci. USA 102(12), 4235-4239 (2005).
64. Mangoni ML, Marcellini HG, Simmaco M. Biological characterization and modes of action of temporins and bombinins H, multiple forms of short and mildly cationic anti-microbial peptides from amphibian skin. J. Pept. Sci. 13(9), 603-613 (2007).
65. Mangoni ML, Papo N, Saugar JM et al. Effect of natural l-to d-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H. Biochemistry 45(13), 4266-4276 (2006).
66. Mangoni ML, Grovale N, Giorgi A, Mignogna G, Simmaco M, Barra D. Structure-function relationships in bombinins H, antimicrobial peptides from Bombina skin secretions. Peptides 21(11), 1673-1679 (2000).
67. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl Acad. Sci. USA 84(15), 5449-5453 (1987).
68. Maloy WL, Kari UP. Structure-activity studies on magainins and other host defense peptides. Biopolymers 37(2), 105-122 (1995).
69. Matsuzaki K. Magainins as paradigm for the mode of action of pore forming polypeptides. Biochim. Biophys. Acta 1376(3), 391-400 (1998).
70. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1462(1-2), 1-10 (1999).
71. Bessalle R, Kapitkovsky A, Gorea A, Shalit I, Fridkin M. All-d-magainin: Chirality, antimicrobial activity and proteolytic resistance. FEBS Lett. 274(1-2), 151-155 (1990).
72. Wade D, Boman A, Wahlin B et al. All-D amino acid-containing channel-forming antibiotic peptides. Proc. Natl Acad. Sci. USA 87(12), 4761-4765 (1990).
73. Guerrero E, Saugar JM, Matsuzaki K, Rivas L. Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob. Agents Chemother. 48(8), 2980-2986 (2004).
74. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1462(1-2), 55-70 (1999).
75. Pestonjamasp VK, Huttner KH, Gallo RL. Processing site and gene structure for the murine antimicrobial peptide CRAMP. Peptides 22(10), 1643-1650 (2001).
76. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75(1), 39-48 (2004).
77. Haines LR, Thomas JM, Jackson AM et al. Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18. PLoS Negl. Trop. Dis. 3(2), e373 (2009).
78. Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J. Biol. Chem. 267(7), 4292-4295 (1992).
79. Bera A, Singh S, Nagaraj R, Vaidya T. Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Mol. Biochem. Parasitol. 127(1), 23-35 (2003).
80. Diaz-Achirica P, Ubach J, Guinea A, Andreu D, Rivas L. The plasma membrane of Leishmania donovani promastigotes is the main target for CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide. Biochem. J. 330 (Pt 1), 453-460 (1998).
81. Rivas L, Andreu D. Cecropin-melittin hybrid peptides as versatile templates in the development of membrane-active antibiotic agents. In: PORE-Forming Peptides and Protein Toxins. Menestrina G, Serra MD, Lazarovici P (Eds). Taylor & Francis Group, NY, USA, 209-314 (2003).
82. Boman HG, Wade D, Boman IA, Wahlin B, Merrifield RB. Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids. FEBS Lett. 259(1), 103-106 (1989).
83. Andreu D, Ubach J, Boman A et al. Shortened cecropin A-melittin hybrids. Significant size reduction retains potent antibiotic activity. FEBS Lett. 296(2), 190-194 (1992).
84. Otvos L Jr. Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci. 11(11), 697-706 (2005).
85. Nicolas P. Multifunctional host defense peptides: Intracellular-targeting antimicrobial peptides. FEBS J. 276(22), 6483-6496 (2009).
86. Luque-Ortega JR, Van't Hof W, Veerman EC, Saugar JM, Rivas L. Human antimicrobial peptide histatin 5 is a cell-penetrating peptide targeting mitochondrial ATP synthesis in Leishmania. FASEB J. 22(6), 1817-1828 (2008).
87. Kavanagh K, Dowd S. Histatins: Antimicrobial peptides with therapeutic potential. J. Pharm. Pharmacol. 56(3), 285-289 (2004).
88. Bowdish DM, Davidson DJ, Hancock RE. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 6(1), 35-51 (2005).
89. Aarbiou J, Ertmann M, Van Wetering S et al. Human neutrophil defensins induce lung epithelial cell proliferation in vitro. J. Leukoc. Biol. 72(1), 167-174 (2002).
90. Koczulla R, Von Degenfeld G, Kupatt C et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111(11), 1665-1672 (2003).
91. Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. 64(12), 4922-4927 (1996).
92. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J. Immunol. 144(2), 662-666 (1990).
93. De Y, Chen Q, Schmidt AP et al. LL-37, the neutrophil granule-and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192(7), 1069-1074 (2000).
94. Tjabringa GS, Aarbiou J, Ninaber DK et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. 171(12), 6690-6696 (2003).
95. Niyonsaba F, Iwabuchi K, Someya A et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106(1), 20-26 (2002).
96. Chen Q, Wade D, Kurosaka K, Wang ZY, Oppenheim JJ, Yang D. Temporin A and related frog antimicrobial peptides use formyl peptide receptor-like 1 as a receptor to chemoattract phagocytes. J. Immunol. 173(4), 2652-2659 (2004).
97. Chertov O, Michiel DF, Xu L et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J. Biol. Chem. 271(6), 2935-2940 (1996).
98. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 68(1), 9-14 (2000).
99. Territo MC, Ganz T, Selsted ME, Lehrer R: MONOCYTE-chemotactic activity of defensins from human neutrophils. J. Clin. Invest. 84(6), 2017-2020 (1989).
100. Zhao H, Kinnunen PK: MODULATION of the activity of secretory phospholipase A2 by antimicrobial peptides. Antimicrob. Agents Chemother. 47(3), 965-971 (2003).
101. Kindrachuk J, Scruten E, Attah-Poku S et al. Stability, toxicity, and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers. Biopolymers 96(1), 14-24 (2011).
102. Wieczorek M, Jenssen H, Kindrachuk J et al. Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem. Biol. 17(9), 970-980 (2010).
103. Giuliani A, Rinaldi AC. Beyond natural antimicrobial peptides: Multimeric peptides and other peptidomimetic approaches. Cell Mol. Life Sci. 68(13), 2255-2266 (2011).
104. Knappe D, Henklein P, Hoffmann R, Hilpert K. Easy strategy to protect antimicrobial peptides from fast degradation in serum. Antimicrob. Agents Chemother. 54(9), 4003-4005 (2010).
105. Yount NY, Bayer AS, Xiong YQ, Yeaman MR. Advances in antimicrobial peptide immunobiology. Biopolymers 84(5), 435-458 (2006).
106. Vouldoukis I, Shai Y, Nicolas P, Mor A. Broad spectrum antibiotic activity of the skin-PYY. FEBS Lett. 380(3), 237-240 (1996).
107. Feder R, Dagan A, Mor A. Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J. Biol. Chem. 275(6), 4230-4238 (2000).
108. Akuffo H, Hultmark D, Engstom A, Frohlich D, Kimbrell D. Drosophila antibacterial protein, cecropin A, differentially affects non-bacterial organisms such as Leishmania in a manner different from other amphipathic peptides. Int. J. Mol. Med. 1(1), 77-82 (1998).
109. Silva PI, Jr., Daffre S, Bulet P. Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider Acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family. J. Biol. Chem. 275(43), 33464-33470 (2000).
110. Davis AJ, Kedzierski L. Recent advances in antileishmanial drug development. Curr. Opin. Investig. Drugs 6(2), 163-169 (2005).